Agilent, ASI Announce Agreement
News Apr 08, 2016
Agilent Technologies Inc. and Applied Spectral Imaging (ASI) have announced they have entered into an agreement to jointly market ASI’s most advanced GenASIs imaging platforms and Agilent’s fluorescence in situ hybridization (FISH) products and solutions, including its Dako Omnis instrument for automated FISH sample processing.
This agreement is expected to bring to pathology labs the components for a fully automated, end-to-end FISH workflow. “We are excited to work with ASI,” said Herman Verrelst, vice president and general manager of Agilent’s Genomics Solutions Division and Clinical Applications Division.
“Difficulty of fluorescence-based molecular analysis has always been a major pain point for our customers. We anticipate that Agilent’s broad portfolio of FISH reagents and instruments, and ASI’s industry-leading computer-aided imaging solutions, will address such critical customer needs and enable laboratories to have a standardized, efficient and high-quality FISH workflow.”
“ASI is proud to partner with Agilent, a global leader in diagnostics that shares our main objective to make patient care better,” said Limor Shiposh, chief executive officer of ASI. “This agreement will position both companies to support customers in all stages of workflows.”
Researchers have used a method to develop a new blood marker capable of detecting whether or not a person has Alzheimer’s disease. If the method is approved for clinical use, the researchers hope eventually to see it used as a diagnostic tool in primary healthcare. This autumn, they will start a trial in primary healthcare to test the technique.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.